Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R.

Cell. 2010 Sep 3;142(5):699-713. doi: 10.1016/j.cell.2010.07.044.

2.

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.

Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K, Majeti R.

MAbs. 2015;7(5):946-56. doi: 10.1080/19420862.2015.1062192.

3.

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.

Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL.

Blood. 2011 Nov 3;118(18):4890-901. doi: 10.1182/blood-2011-02-338020. Epub 2011 Aug 9.

5.

Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.

Lewis TS, McCormick RS, Emmerton K, Lau JT, Yu SF, McEarchern JA, Grewal IS, Law CL.

Clin Cancer Res. 2011 Jul 15;17(14):4672-81. doi: 10.1158/1078-0432.CCR-11-0479. Epub 2011 May 24.

6.

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.

Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R.

PLoS One. 2015 Sep 21;10(9):e0137345. doi: 10.1371/journal.pone.0137345. eCollection 2015.

7.

Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.

Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L, Rosenberg E, Galun E, Avigdor A, Eizenberg O, Peled A, Nagler A.

Clin Cancer Res. 2013 Jul 1;19(13):3495-507. doi: 10.1158/1078-0432.CCR-12-3015. Epub 2013 May 1.

8.
9.

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.

J Immunother. 2001 May-Jun;24(3):263-71.

PMID:
11394505
10.

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL.

Cell. 2009 Jul 23;138(2):286-99. doi: 10.1016/j.cell.2009.05.045.

11.

Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro.

Wang Y, Yin C, Feng L, Wang C, Sheng G.

Genet Mol Res. 2015 May 25;14(2):5630-41. doi: 10.4238/2015.May.25.15.

12.

Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.

Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM.

J Immunother. 2009 Jul-Aug;32(6):622-31. doi: 10.1097/CJI.0b013e3181ab23f1.

PMID:
19483647
13.

Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.

Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B.

Clin Cancer Res. 2009 Nov 1;15(21):6582-94. doi: 10.1158/1078-0432.CCR-09-1234. Epub 2009 Oct 27.

14.

Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R.

Cancer Res. 2011 Feb 15;71(4):1374-84. doi: 10.1158/0008-5472.CAN-10-2238. Epub 2010 Dec 21.

15.

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.

Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL.

Leukemia. 2012 Dec;26(12):2538-45. doi: 10.1038/leu.2012.141. Epub 2012 May 30.

PMID:
22648449
16.

The therapeutic use of rituximab in non-Hodgkin's lymphoma.

Marcus R, Hagenbeek A.

Eur J Haematol Suppl. 2007 Jan;(67):5-14. Review.

PMID:
17206982
17.

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.

Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, Weissman IL.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8. doi: 10.1073/pnas.1305569110. Epub 2013 May 20.

18.

CD47/SIRP╬▒ blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies.

Xu L, Wang S, Li J, Li B.

Biochem Biophys Res Commun. 2019 Feb 12;509(3):739-745. doi: 10.1016/j.bbrc.2018.12.175. Epub 2019 Jan 3.

PMID:
30611570
19.

Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.

Zhao L, Xie F, Tong X, Li H, Chen Y, Qian W, Duan S, Zheng J, Zhao Z, Li B, Zhang D, Zhao J, Dai J, Wang H, Hou S, Guo Y.

MAbs. 2014 May-Jun;6(3):740-8. doi: 10.4161/mabs.28613. Epub 2014 Mar 26.

20.

Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.

Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.

J Immunother. 2007 Jan;30(1):64-74.

PMID:
17198084

Supplemental Content

Support Center